13F Holdings
中文EN

SCNI Scinai Immunotherapeutics Ltd.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1611747 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY99.2%
TTM net income YoY-273.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-202.3%
Operating margin-575.3%
Net margin-633.6%
FCF margin-461.9%
EBITDA margin-466.9%

Returns

ROE-91.9%
ROA-66.3%
ROIC (approx.)-82.4%
Asset turnover0.10x

Leverage & solvency

Liabilities / assets30.3%
Debt / equity0.00x
Current ratio1.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-18.2%
Payout ratio—
Capex / revenue1.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31 · USDFY20242024-12-31 · USDFY20232023-12-31 · USDFY20222022-12-31 · USDFY20212021-12-31 · USD
Income statement
Revenue$1.31M$658,000——5,000EUR
Cost of revenue$3.96M$1.24M———
Gross profit-$2.65M-$580,000———
R&D expense$2.37M$5.53M$5.21M$5.76M$3.25M
SG&A expense$2.52M$2.53M$4.50M$5.30M$7.62M
Operating income-$7.54M-$8.64M-$9.71M-$11.06M-$10.86M
Interest expense——$343,000$351,000$336,000
Net income-$8.31M$4.80M-$6.50M-$5.80M-$8.21M
EBITDA-$6.12M-$6.99M-$9.19M-$10.50M-$10.39M
EPS (basic)——0.000.01-0.02
EPS (diluted)——0.000.01-0.02
Weighted avg. shares (diluted)9.34B3.23B1.56B754.08M564.58M
Balance sheet
Cash & equivalents$1.66M$1.96M$4.87M$14.21M$17.52M
Receivables$73,000$83,000——$325,000
Current assets$2.05M$2.39M$5.45M$14.37M$17.84M
PP&E, net$7.79M$9.19M$10.82M$11.24M$12.39M
Total assets$11.63M$13.45M$17.47M$27.07M$32.04M
Current liabilities$1.58M$1.81M$1.78M$2.34M$2.44M
Short-term debt———$382,000$375,000
Total liabilities$3.52M$3.47M$22.04M$28.83M$31.05M
Shareholders' equity$8.10M$9.98M-$4.57M-$1.76M$982,000
Shares outstanding13.87B3.41B1.86B989.29M739.05M
Cash flow statement
Operating cash flow-$6.03M-$6.33M-$9.38M-$7.26M-$7.43M
Capital expenditure$24,000$12,000$637,000$836,000$139,000
Free cash flow-$6.05M-$6.35M-$10.02M-$8.10M-$7.57M
Investing cash flow-$24,000-$12,000-$637,000-$836,000-$139,000
Financing cash flow$5.77M$3.44M$1.09M$6.78M$21.43M
Depreciation & amortization$1.42M$1.65M$514,000$562,000$471,000
Stock-based compensation$303,000$682,000$1.14M$1.60M$2.76M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.